Once Weekly (QW) Basal Insulin Fc (BIF) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in Three Patient Populations Studied during Phase 2—Clinical Insights from CGM Assessments
In this medfyle
Compared to insulin degludec, BIF (a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain) administered once a week achieves similar glycemic control as determined by continuous glucose monitoring.
About this Medfyle
This content is intended for an international audience of non-UK healthcare professionals. The content is made available through a licensing agreement between Infomedica and the American Diabetes Association (ADA).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the ADA.
©2023 Infomedica-Medfyle. All rights reserved
